NVS Jan 2025 100.000 call

OPR - OPR Delayed price. Currency in USD

Add to watchlist

14.20

0.00

(0.00%)

At close: 01:19PM EDT

Loading interactive chart…

Zacks
Is a Beat in the Cards for Incyte (INCY) in Q2 Earnings?
On Incyte's (INCY) second-quarter 2024 earnings call, investors' focus is likely to be on the sales performance of its lead drug, Jakafi, which has been facing stiff competition.
Zacks
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Zacks
Ionis (IONS) Completes Enrolment for Rare Disease Drug Study
Ionis' (IONS) late-stage study is evaluating zilganersen in a rare neurological disorder called Alexander disease. Top-line data from this study is expected by the end of the next year.